Gut reaction in treating IBD

I reported previously (see here) on BiomX. The Israeli biotech has now partnered with Janssen – the therapy R&D arm of Johnson & Johnson. BiomX’s XMarker microbiome-based platform will be used to classify responders to inflammatory bowel disease (IBD) therapies.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *